RU2004134571A - Лечение гипертензии у женщин, подвергающихся гормонзаместительной терапии - Google Patents
Лечение гипертензии у женщин, подвергающихся гормонзаместительной терапии Download PDFInfo
- Publication number
- RU2004134571A RU2004134571A RU2004134571/14A RU2004134571A RU2004134571A RU 2004134571 A RU2004134571 A RU 2004134571A RU 2004134571/14 A RU2004134571/14 A RU 2004134571/14A RU 2004134571 A RU2004134571 A RU 2004134571A RU 2004134571 A RU2004134571 A RU 2004134571A
- Authority
- RU
- Russia
- Prior art keywords
- drsp
- estradiol
- amount
- hypertension
- patient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/553—Renin inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/556—Angiotensin converting enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (17)
1. Способ снижения кровяного давления и осуществления гормонзаместительной терапии (ГЗТ) у страдающей гипертензией женщины, заключающийся в том, что пациентке вводят дроспиренон (ДРСП) в количестве 0,5-3 мг/день и 17β-эстрадиол в количестве 1-3 мг/день.
2. Способ по п.1, заключающийся, кроме того, в том, что пациенту вводят гипотензивное лекарственное средство.
3. Способ по п.2, где пациентка начинает принимать гипотензивное лекарственное средство до начала введения ДРСП и 17β-эстрадиола.
4. Способ по п.2, где гипотензивное лекарственное средство вводят в сочетании с введением ДРСП и 17β-эстрадиола.
5. Способ по п.2, где введение гипотензивного лекарственного средства начинают после начала введения ДРСП и 17β-эстрадиола.
6. Способ по п.2, где гипотензивное лекарственное средство представляет собой диуретик, α-адренергический блокатор, β-адренергический блокатор, агент, воздействующий на ЦНС, блокатор адренергических нейронов, вазодилататор, ингибитор ангиотензин I-превращающего фермента (АСЕ), блокатор кальциевых каналов, ингибитор ренина или их комбинацию.
7. Способ по п.6, где гипотензивное лекарственное средство представляет собой ингибитор АСЕ.
8. Способ по п.7, где ингибитор АСЕ представляет собой беназеприл, каптоприл, эналаприл, эналаприлат, фосиноприл, лисиноприл, пентоприл, хинаприл, хинаприлат, рамиприл, трансолаприл или зофеноприл.
9. Способ по п.1, где ДРСП и 17β-эстрадиол вводят орально, трансдермально или путем инъекции.
10. Способ по п.9, где ДРСП и 17β-эстрадиол вводят орально.
11. Способ по п.2, где гипотензивное лекарственное средство представляет собой малеат эналаприла.
12. Способ по п.1, где пациентка находится на перименопаузальной, менопаузальной или постменопаузальной фазе.
13. Способ по п.1, где гипертензия представляет собой гипертензию слабой или серьезной степени.
14. Способ по п.1, где количество ДРСП составляет 3 мг и количество 17β-эстрадиола составляет 1 мг.
15. Способ по п.1, где количество ДРСП составляет 2 мг и количество 17β-эстрадиола составляет 1 мг.
16. Способ по п.1, где количество ДРСП составляет 1 мг и количество 17β-эстрадиола составляет 1 мг.
17. Способ по п.1, где количество ДРСП составляет 0,5 мг и количество 17β-эстрадиола составляет 1 мг.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37543902P | 2002-04-26 | 2002-04-26 | |
| US60/375,439 | 2002-04-26 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2004134571A true RU2004134571A (ru) | 2005-07-10 |
| RU2373940C2 RU2373940C2 (ru) | 2009-11-27 |
Family
ID=29270642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2004134571/14A RU2373940C2 (ru) | 2002-04-26 | 2003-03-24 | Лечение гипертензии у женщин, подвергающихся гормонзаместительной терапии |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20040034001A1 (ru) |
| EP (2) | EP1499323A1 (ru) |
| JP (1) | JP2005528408A (ru) |
| KR (1) | KR20040104632A (ru) |
| CN (1) | CN1649596A (ru) |
| AU (2) | AU2003239162A1 (ru) |
| BR (1) | BR0309780A (ru) |
| CA (1) | CA2483554A1 (ru) |
| CR (1) | CR7571A (ru) |
| EC (1) | ECSP045456A (ru) |
| HK (1) | HK1079997A1 (ru) |
| HR (1) | HRP20041121A2 (ru) |
| IL (1) | IL164808A0 (ru) |
| ME (1) | MEP35908A (ru) |
| MX (1) | MXPA04010682A (ru) |
| NO (1) | NO20045147L (ru) |
| NZ (1) | NZ548754A (ru) |
| PL (1) | PL372055A1 (ru) |
| RS (1) | RS93804A (ru) |
| RU (1) | RU2373940C2 (ru) |
| UA (1) | UA87437C2 (ru) |
| WO (1) | WO2003090755A1 (ru) |
| ZA (1) | ZA200409548B (ru) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020132801A1 (en) * | 2001-01-11 | 2002-09-19 | Schering Aktiengesellschaft | Drospirenone for hormone replacement therapy |
| US7786101B2 (en) * | 2002-11-05 | 2010-08-31 | Bayer Schering Pharma Ag | Cardiovascular protection using anti-aldosteronic progestins |
| DE102004016779A1 (de) * | 2004-04-01 | 2006-01-19 | Schering Ag | Drospirenonhaltige Zubereitungen zur transdermalen Anwendung |
| PL1750862T3 (pl) * | 2004-06-04 | 2011-06-30 | Teva Pharma | Kompozycja farmaceutyczna zawierająca irbesartan |
| US20070275941A1 (en) * | 2006-05-17 | 2007-11-29 | Vladimir Hanes | Salt sensitivity and prevention of hypertension with drospirenone |
| US20090035373A1 (en) * | 2007-07-31 | 2009-02-05 | Katrin Mittmann | Pharmaceutical composition for contraception and blood pressure regulation, kit for contraception containing same and method of production of same |
| US20090035374A1 (en) * | 2007-07-31 | 2009-02-05 | Katrin Mittmann | Method of making a single-stage pharmaceutical preparation for oral therapy to regulate blood pressure and kit containing same |
| US20130137664A1 (en) * | 2010-04-15 | 2013-05-30 | Bayer Intellectual Property Gmbh | Low-dosed solid oral dosage forms for hrt |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| WO2013078422A2 (en) | 2011-11-23 | 2013-05-30 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| RU2016143081A (ru) | 2014-05-22 | 2018-06-26 | Терапьютиксмд, Инк. | Натуральные комбинированные гормонозаместительные составы и терапии |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| RU2648470C2 (ru) * | 2016-03-03 | 2018-03-26 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Уральский государственный медицинский университет Министерства здравоохранения Российской Федерации" (ГБОУ ВПО УГМУ Минздрава России) | Способ оптимизации лечения женщин кардиотропной терапией и заместительной гормональной терапией при эстрогенодефиците с артериальной гипертензией в позднем репродуктивном периоде |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| WO2017173071A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4217347A (en) * | 1977-12-27 | 1980-08-12 | E. R. Squibb & Sons, Inc. | Method of treating hypertension and medicaments therefor |
| US5001113A (en) | 1987-10-14 | 1991-03-19 | Merck & Co., Inc. | Di- or tripeptide renin inhibitors containing lactam conformational restriction in ACHPA |
| US6300362B1 (en) | 1990-07-25 | 2001-10-09 | Novartis Ag (Formerly Sandoz Ltd.) | Stabilized pharmaceutical compositions comprising acid donors |
| DE4344462C2 (de) * | 1993-12-22 | 1996-02-01 | Schering Ag | Zusammensetzung für die Empfängnisverhütung |
| US5897539A (en) * | 1995-09-28 | 1999-04-27 | Schering Aktiengesellschaft | Hormone replacement therapy method and hormone dispenser |
| US6083528A (en) | 1995-09-28 | 2000-07-04 | Schering Aktiengesellschaft | Hormone replacement therapy method and hormone dispenser |
| KR0156678B1 (ko) | 1996-01-11 | 1998-10-15 | 이상윤 | 안지오텐신 전환효소 저해제 |
| US5789442A (en) * | 1996-01-18 | 1998-08-04 | Schering Aktiengesellschaft | Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combination with estrogen or progesterone and/or other agents |
| DE19633685C1 (de) | 1996-08-12 | 1997-10-09 | Schering Ag | Verfahren zur Herstellung von Drospirenon (6beta,7beta;15 beta,16beta-Dimethyl-en-3-oxo-17alpha-pregn-4-en-21,17-carbolacton, DRSP) sowie 7alpha-(3-Hydroxy-1-propyl)-6beta,7beta;15beta, 16beta-dimethylen-5beta-androstan-3beta,5,17beta-triol (ZK 92836) und 6beta,7beta;15beta,16beta-dimethylen-5beta-hydroxy-3-oxo-17alpha-androstan-21,17-carbolacton (90965) als Zwischenprodukte des Verfahrens |
| DE19651000A1 (de) * | 1996-12-01 | 1998-06-04 | Schering Ag | Oxyiminopregnancarbolactone |
| US20010056068A1 (en) * | 1998-03-04 | 2001-12-27 | Kristof Chwalisz | Method of treatment and prevention of nitric oxide deficiency-related disorders with citrulline and citrulline derivatives |
| UA74141C2 (ru) * | 1998-12-09 | 2005-11-15 | Дж.Д. Сірл Енд Ко. | Фармацевтическая композиция на основе тонкодисперсного эплеренона (варианты), способ ее получения и способ лечения расстройств, опосредованных альдостероном (варианты) |
| KR101019361B1 (ko) * | 1999-08-31 | 2011-03-07 | 바이엘 쉐링 파마 악티엔게젤샤프트 | 피임약으로서의 사용을 위한 에티닐에스트라디올과드로스피렌온의 약학적 조합 |
| US20030096798A1 (en) * | 1999-11-09 | 2003-05-22 | Williams Gordon H. | Methods for the treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist |
| ES2332226T3 (es) * | 2000-01-18 | 2010-01-29 | Bayer Schering Pharma Aktiengesellschaft | Composiciones farmaceuticas que comprenden drospirenona. |
| US20020132801A1 (en) * | 2001-01-11 | 2002-09-19 | Schering Aktiengesellschaft | Drospirenone for hormone replacement therapy |
| CA2419256A1 (en) * | 2000-08-28 | 2002-03-07 | Kenton N. Fedde | Use of an aldosterone receptor antagonist to improve cognitive function |
| US7786101B2 (en) * | 2002-11-05 | 2010-08-31 | Bayer Schering Pharma Ag | Cardiovascular protection using anti-aldosteronic progestins |
-
2003
- 2003-03-24 AU AU2003239162A patent/AU2003239162A1/en not_active Abandoned
- 2003-03-24 EP EP03733879A patent/EP1499323A1/en not_active Ceased
- 2003-03-24 ME MEP-359/08A patent/MEP35908A/xx unknown
- 2003-03-24 BR BR0309780-3A patent/BR0309780A/pt not_active IP Right Cessation
- 2003-03-24 KR KR10-2004-7017196A patent/KR20040104632A/ko not_active Application Discontinuation
- 2003-03-24 EP EP08075587A patent/EP1982719A1/en not_active Withdrawn
- 2003-03-24 CA CA002483554A patent/CA2483554A1/en not_active Abandoned
- 2003-03-24 MX MXPA04010682A patent/MXPA04010682A/es unknown
- 2003-03-24 NZ NZ548754A patent/NZ548754A/en not_active IP Right Cessation
- 2003-03-24 PL PL03372055A patent/PL372055A1/xx not_active Application Discontinuation
- 2003-03-24 UA UA20041109649A patent/UA87437C2/ru unknown
- 2003-03-24 JP JP2003587389A patent/JP2005528408A/ja active Pending
- 2003-03-24 RU RU2004134571/14A patent/RU2373940C2/ru not_active IP Right Cessation
- 2003-03-24 RS YU93804A patent/RS93804A/sr unknown
- 2003-03-24 CN CNA038093871A patent/CN1649596A/zh active Pending
- 2003-03-24 WO PCT/US2003/012596 patent/WO2003090755A1/en active Application Filing
- 2003-03-24 IL IL16480803A patent/IL164808A0/xx unknown
- 2003-04-24 US US10/421,940 patent/US20040034001A1/en not_active Abandoned
-
2004
- 2004-11-05 CR CR7571A patent/CR7571A/es not_active Application Discontinuation
- 2004-11-24 HR HR20041121A patent/HRP20041121A2/hr not_active Application Discontinuation
- 2004-11-25 ZA ZA200409548A patent/ZA200409548B/xx unknown
- 2004-11-25 NO NO20045147A patent/NO20045147L/no not_active Application Discontinuation
- 2004-11-26 EC EC2004005456A patent/ECSP045456A/es unknown
-
2006
- 2006-01-04 HK HK06100150.0A patent/HK1079997A1/zh unknown
-
2008
- 2008-08-04 AU AU2008203497A patent/AU2008203497A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MEP35908A (en) | 2011-02-10 |
| ECSP045456A (es) | 2005-01-28 |
| HRP20041121A2 (en) | 2005-02-28 |
| CA2483554A1 (en) | 2003-11-06 |
| NO20045147L (no) | 2005-01-18 |
| HK1079997A1 (zh) | 2006-04-21 |
| CR7571A (es) | 2006-02-07 |
| AU2003239162A1 (en) | 2003-11-10 |
| JP2005528408A (ja) | 2005-09-22 |
| KR20040104632A (ko) | 2004-12-10 |
| NZ548754A (en) | 2008-06-30 |
| EP1982719A1 (en) | 2008-10-22 |
| US20040034001A1 (en) | 2004-02-19 |
| RS93804A (sr) | 2006-10-27 |
| UA87437C2 (ru) | 2009-07-27 |
| CN1649596A (zh) | 2005-08-03 |
| PL372055A1 (en) | 2005-07-11 |
| AU2008203497A1 (en) | 2008-08-28 |
| RU2373940C2 (ru) | 2009-11-27 |
| BR0309780A (pt) | 2005-03-22 |
| EP1499323A1 (en) | 2005-01-26 |
| IL164808A0 (en) | 2005-12-18 |
| ZA200409548B (en) | 2010-05-26 |
| WO2003090755A1 (en) | 2003-11-06 |
| MXPA04010682A (es) | 2004-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2004134571A (ru) | Лечение гипертензии у женщин, подвергающихся гормонзаместительной терапии | |
| Antihypertensive et al. | Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) | |
| AU683262B2 (en) | A method of treating cardiovascular disorders using a combination of a renin angiotensin system inhibitor and an endothelin antagonist | |
| Sever | Candesartan cilexetil: a new, long-acting, effective angiotensin II type 1 receptor blocker. | |
| IL148127A (en) | Use of ramipril or its pharmaceutical salt to prepare or prevent heart events in high-risk patients without evidence of left ventricular dysfunction | |
| EP0643580A1 (en) | Combinations of ace inhibitors and diuretics | |
| VAUGHAN jR et al. | Hemodialysis-resistant hypertension: control with an orally active inhibitor of angiotensin-converting enzyme | |
| CA2372785A1 (en) | Pharmaceutical combination of angiotensin ii antagonists and angiotensin i converting enzyme inhibitors | |
| Hansson et al. | The Hypertension Optimal Treatment (HOT) Study: 12-month data on blood pressure and tolerability. With special reference to age and gender | |
| Kostis | Angiotensin converting enzyme inhibitors. I. Pharmacology | |
| EP0991424B1 (en) | Pharmaceutical compositions comprising an aldose reductase inhibitor and an ace inhibitor | |
| CA2117782C (en) | Use of renin-angiotensin antagonist for reducing post myocardial infarct morbidity and mortality | |
| Himmelmann et al. | Remikiren (Ro 42-5892)—An orally active renin inhibitor in essential hypertension Effects on blood pressure and the renin-angiotensin-aldosterone system | |
| Riley Jr et al. | Clinical pharmacology and therapeutic applications of the new oral converting enzyme inhibitor, enalapril | |
| Brunner et al. | Enhancement by diuretics of the antihypertensive action of long-term angiotensin converting enzyme blockade | |
| YESILBURSA | Effects of fosinopril treatment on blood pressure during physical and mental stress test in essential hypertension | |
| DeQuattro et al. | Equivalent reduction of proteinuria in hypertensives by either nifedipine GITS or enalapril: disparate effects on neurohormones and ambulatory blood pressure and the influence of salt | |
| Ruilope | Proven benefits of angiotensin receptor blockers in the progression of renal disease | |
| Lavezzaro et al. | Ketanserin and captopril interaction in the treatment of essential hypertensives | |
| Grandi et al. | A095: Chronic treatment with ace-inhibitors induces left ventricular changes independently of blood pressure decrease | |
| Osterziel et al. | Circadian rhythm of blood pressure in congestive heart failure and effects of ACE inhibitors | |
| US20080114046A1 (en) | Pharmaceutical Combination of Angiotensin II Antagonists and Angiotensin I Converting Enzyme Inhibitors | |
| Elliott | Tuesday, May 15, 5: 00 PM to 7: 00 PM Disruption of Renin-Angiotensin System: Future Directions*: Do ACE-inihibitors and angiotensin receptor blockers provide equivalent control of blood pressure? | |
| Marcantoni et al. | Management of hypertension in renal disease | |
| White | Tuesday, May 15, 5: 00 PM to 7: 00 PM Disruption of Renin-Angiotensin System: Future Directions*: Patterns of blood pressure responses: Day and night variations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20110325 |